title: Fair and effective resource allocation in cancer care: uncharted territory?
authors.forename: J A
authors.initials: JA
authors.lastname: Green
authors.forename: C
authors.initials: C
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Cribb
authors.forename: B
authors.initials: B
authors.lastname: Brecher
authors.forename: M
authors.initials: M
authors.lastname: Evans
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D035843:Biomedical Research; D003363:Cost Control; D003362:Cost-Benefit Analysis; D003466:Cultural Characteristics; D018572:Disease-Free Survival; D033161:Government Regulation; D015276:Health Care Rationing / Q000592:standards*; D006801:Humans; D038622:Internationality; D009369:Neoplasms / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D012106:Research; D040841:Resource Allocation; D018570:Risk Assessment; D012935:Social Justice; D012945:Social Values; D015996:Survival Rate; D006113:United Kingdom; D014481:United States; D026712:Value of Life